Phase Ib/II Study of Ivosidenib Plus Venetoclax With or Without Azacitidine in Patients With IDH1-Mutated Hematologic Malignancies

May 29-31, 2020; Online at meetings.asco.org/am
Combination of ivosidenib plus venetoclax with or without azacitidine was well tolerated and effective in patients with IDH1-mutated hematologic malignancies.
Format: Microsoft PowerPoint (.ppt)
File Size: 240 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

In this commentary from Clinical Care Options (CCO), Dr. Jennifer Woyach discusses patient education and shared decision making in CLL

Jennifer Woyach, MD Released: November 17, 2021

A downloadable slideset from Clinical Care Options (CCO) on current management of AML tailored for nurses and physician assistants.

Released: November 11, 2021

Gain key clinical insights quickly with this short slideset from CCO on new advances using BTK inhibitors in the treatment of CLL.

person default Seema Ali Bhat, MD Talha Munir, MBBS, MRCP, FRCPath Released: November 4, 2021

Expert commentary on managing patients with CML and comorbidities, from Clinical Care Options (CCO)

Jorge Cortes, MD Released: November 3, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue